Invited Commentary

Li and colleagues address the important and timely topic of patient completion of multimodality therapy for advanced gastric cancer.1 Although there has been an improvement in survival in patients with gastric cancer over the past few decades, the 5-year overall survival remains low, at 31.5%.2 Surgical resection with lymph node dissection is the mainstay of potential curative treatment for early-stage disease, while multimodality therapy (MMT) has been shown to increase survival in patients with locoregional or advanced gastric cancer, as addressed in this study.
Source: Journal of the American College of Surgeons - Category: Surgery Authors: Tags: Invited commentary Source Type: research